other material
confidence high
sentiment positive
materiality 0.85
Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis
Oruka Therapeutics, Inc.
- ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
- Secondary endpoints: PASI 90 82.5%, IGA 0 63.5%, IGA 0/1 84.1% vs 4.8% placebo.
- Safety: well-tolerated; no serious TEAEs, no discontinuations; URI 19% vs 14% placebo.
- Updated Phase 1 PK/PD data support once-yearly dosing; concentrations above effective trough for 52 weeks.
- Longer-term EVERLAST-A data (Week 28, 52-wk) expected 2H 2026; EVERLAST-B Phase 2b data expected 2027.